17-Beta-3-Furyl-5Beta,14Beta-Androstane Derivatives for Renal Protection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments and medications do not effectively address proteinuria, glomerulosclerosis, and renal failure, particularly in normotensive subjects, as existing compounds do not target the specific modulation of glomerular permeability and podocyte protein expression.
Innovation Solution
The use of 17-β-(3-furyl)-5β, 14β-androstane derivatives, specifically the compound rostatfuroxin, which acts as an antiproteuremic, antiglomerulosclerotic, and anti-renal failure agent by modulating podocyte protein expression and glomerular permeability, thereby preventing proteinuria and renal damage.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing compounds are used for treating renal diseases, then general treatment is provided, but specific modulation of glomerular permeability and podocyte protein expression is not achieved
Solution Approach 1:
The patent applies local quality by designing a compound with specific structural features (17-β-(3-furyl)-5β,14β-androstane derivative) that target specific biological structures (podocyte proteins like nephrin and synaptopodin) rather than acting generally. The molecular structure is optimized to interact specifically with podocyte cytoskeletal components, providing localized therapeutic action at the glomerular filtration barrier level.
Solution Approach 2:
The patent employs parameter changes by modifying the chemical structure parameters of the androstane derivative (specific substituents at position 17-β, stereochemistry at 5β and 14β positions) to achieve optimal binding affinity and biological activity. These structural parameter modifications enable the compound to specifically modulate podocyte protein expression and glomerular permeability parameters.
2Reliability
If existing medications are used, then broad coverage is provided, but proteinuria reduction and renal function improvement are insufficient
Solution Approach 1:
The patent uses the androstane derivative compound as an intermediary substance that mediates between the administered drug and the target podocyte proteins. The compound acts as a molecular mediator that transfers the therapeutic effect by binding to and stabilizing podocyte cytoskeletal proteins, thereby indirectly protecting the glomerular filtration barrier and reducing proteinuria.
Solution Approach 2:
The patent applies preliminary action by administering the compound before significant renal damage occurs or at early stages of disease progression. The compound proactively stabilizes podocyte proteins and prevents the breakdown of the glomerular filtration barrier, rather than merely treating established damage. This preventive approach is evident in studies showing reduced proteinuria when treatment is initiated early.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Compound of formula (I), wherein the symbol have the meaning reported in the text; for preparing a medicament for the prevention and/or treatment of proteinuria, glomerulosclerosis or renal failure.